Report Highlights

UK Urinary Catheters: Market Overview

The UK urinary catheter market is one of the most institutionally structured medical device markets in Europe, overwhelmingly anchored to NHS procurement cycles rather than private purchasing. Valued at USD 312.4 million in 2024, the market is distinguished by its high penetration of intermittent catheters relative to other European markets, driven by decades of clinical guidelines favouring self-catheterisation to reduce catheter-associated urinary tract infections (CAUTIs). NHS England accounts for approximately 85% of total catheter spend, with the private hospital sector and community care settings comprising the remainder.

Structurally, the UK market differs from the global norm in three important ways. First, reimbursement is handled through GP prescription pads under the Drug Tariff — Part IX specifically covers urinary catheters — allowing community patients to obtain products directly from dispensing chemists, creating a dual hospital-community distribution dynamic unusual in peer markets. Second, Scotland, Wales, and Northern Ireland operate separate procurement frameworks, requiring country-specific access strategies. Third, the Medicines and Healthcare products Regulatory Agency (MHRA) applies UK Conformity Assessed (UKCA) marking requirements post-Brexit, adding a distinct regulatory compliance layer absent in EU-focused strategies.

Growth Drivers in the UK Urinary Catheter Market

Three structural demand drivers underpin market growth through 2032. The ageing UK population is the most powerful force: NHS England projects that adults aged 65 and over will comprise 24% of the population by 2030, and urinary retention, benign prostatic hyperplasia, and neurogenic bladder conditions scale directly with age. The NHS Long Term Plan commits to expanding community and home-based care, channelling more catheter usage into community nursing and self-management pathways where product volumes per patient tend to be higher than acute hospital settings.

The second driver is the NHS CAUTI reduction programme, which mandates catheter care bundles across all NHS trusts under NHS Improvement's CAUTI Framework 2023. This programme actively promotes intermittent catheters over indwelling Foley types, expanding the addressable product volume. Third, the growing prevalence of spinal cord injuries and multiple sclerosis — conditions managed by NHS specialist neurology and urology centres — sustains consistent demand for hydrophilic-coated intermittent catheters, a premium product segment where LoFric (Wellspect), SpeediCath (Coloplast), and GentleCath (Hollister) are the primary beneficiaries. NHS prescribing data shows hydrophilic catheter volumes growing at above-market rates nationally.

Market Restraints and Entry Barriers

The dominant entry barrier is NHS Supply Chain framework dependency. NHS trusts are legally required to source medical devices through approved procurement frameworks where available; the RM6167 Medical Devices and Clinical Products framework administered by NHS Supply Chain is the primary route for catheter procurement. New entrants that have not secured listing under this framework or an equivalent Crown Commercial Service agreement face effective exclusion from the majority of hospital contracts. Framework re-tendering cycles of three to four years mean that a missed cycle translates to years of delayed market access, regardless of product superiority.

Regulatory compliance under the post-Brexit UKCA marking regime represents a secondary but significant barrier. Manufacturers must either obtain UKCA certification through a UK Approved Body — a category with limited capacity following Brexit — or rely on the transitional acceptance of CE marking, which the MHRA has extended but not permanently guaranteed. The Drug Tariff Part IX reimbursement listing process for community dispensing adds a further administrative hurdle, requiring separate engagement with NHS Business Services Authority and demonstrating clinical equivalence. Collectively, these regulatory and procurement barriers mean that the average time from market entry decision to material revenue in the UK is 24 to 36 months longer than in comparable EU markets.

Market Opportunities in the UK

The most immediate opportunity lies in the community and home-care catheter delivery segment. NHS integrated care systems (ICSs) — 42 of which were established under the Health and Care Act 2022 — are actively redesigning pathways to shift catheter management out of secondary care. Suppliers offering complete catheter management services, including delivery, nurse training, and digital monitoring, hold a differentiated value proposition that NHS commissioners are actively seeking. The addressable market for home-delivered catheter supplies in England alone is estimated at GBP 90 million annually, with significant scope for consolidation among current fragmented providers.

A second opportunity exists in antimicrobial and anti-biofilm catheter technologies. The UK government's National Action Plan on Antimicrobial Resistance 2019–2024 (extended to 2029) creates institutional pressure on NHS trusts to adopt technologies that demonstrably reduce infection-related antibiotic prescribing. Catheters incorporating silver alloy coatings or nitrofurazone impregnation are positioned directly within this policy priority, and NICE technology appraisal pathways provide an accelerated route to NHS adoption for devices with strong health economic evidence. Companies that commission NHS-based health economic studies in 2025 and 2026 are positioned to secure NICE guidance recommendations ahead of the next NHS Supply Chain framework cycle.

Market at a Glance

Leading Market Participants

• Coloplast UK
• Wellspect HealthCare (Dentsply Sirona subsidiary)
• Hollister Incorporated
• C. R. Bard (BD UK)
• Teleflex Medical
• Medline Industries
• B. Braun Medical UK
• Pennine Healthcare
• Bard Medical (part of BD)
• Liberator Medical (part of Cooper Surgical)

Regulatory and Policy Environment

Urinary catheters are classified as Class IIa medical devices under UK Medical Device Regulations 2002 (as amended), overseen by the MHRA. Following the UK's departure from the EU, manufacturers must obtain UKCA marking through a UK-based Approved Body; the MHRA has granted a transitional period allowing CE-marked devices to remain on the UK market until June 2028, after which UKCA certification is mandatory. The NHS Drug Tariff Part IX, administered by NHS Business Services Authority, governs reimbursement pricing for catheters dispensed in the community, with listed prices reviewed annually. NHS Supply Chain's RM6167 framework is the primary procurement vehicle for acute trust purchasing.

NICE published guidance on urinary catheters including Medtech Innovation Briefings (MIBs) that directly influence formulary decisions across NHS trusts. The NHS England CAUTI Prevention Programme, operating under NHS Improvement's patient safety agenda, mandates catheter care bundle implementation across all acute trusts, with compliance monitored through NHS Safety Thermometer metrics. The UK Antimicrobial Resistance National Action Plan extends to 2029 and creates policy pressure favouring antimicrobial catheter adoption. Scotland operates under the Scottish Government's National Procurement Framework through National Services Scotland, while Wales procurement is handled through NHS Wales Shared Services Partnership — each requiring separate submissions, clinical evaluations, and pricing agreements from market participants.

Long-Term Outlook for the UK Urinary Catheter Market

By 2032, the UK urinary catheter market will be substantially larger and more complex than today, driven by demographic expansion, NHS pathway restructuring, and technology upgrades across the product range. The shift from acute hospital to community-based catheter management — accelerated by ICS commissioning models — will redistribute revenue toward home delivery and community nursing service suppliers. Intermittent catheter products, particularly hydrophilic-coated and pre-lubricated variants, will account for a majority of new prescriptions as NHS CAUTI reduction targets become embedded in trust performance frameworks.

Technology will differentiate leaders from followers by 2032. Digital catheter monitoring, connected devices that track voiding patterns, and antimicrobial material innovations will command premium pricing within NHS value-based procurement assessments. Companies that have invested in health economics research and secured NICE recognition by 2027 will hold defensible positions in the next NHS Supply Chain framework cycle. Competitive intensity from European manufacturers seeking post-Brexit UK re-entry via UKCA compliance will increase, but the distribution and procurement infrastructure advantages held by established NHS framework suppliers will remain significant barriers to rapid displacement of incumbent market leaders.